P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib.
Zhou XR, Li X, Liao LP, Han J, Huang J, Li JC, Tao HR, Fan SJ, Chen ZF, Li Q, Chen SJ, Ding H, Yang YX, Zhou B, Jiang HL, Chen KX, Zhang YY, Huang CX, Luo C.
Zhou XR, et al. Among authors: li x, li q, li jc.
Acta Pharmacol Sin. 2022 Feb;43(2):457-469. doi: 10.1038/s41401-021-00643-2. Epub 2021 Apr 13.
Acta Pharmacol Sin. 2022.
PMID: 33850273
Free PMC article.